

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Withdrawn, Currently Amended): A method for treating a patient suffering from a carcinoma in which Hsp47 is expressed on the surface of at least some of cells, comprising administering to the patient an effective amount of an agent comprising a targeting moiety which binds specifically to an external domain of Hsp47, wherein said targeting moiety comprises a peptide of claim 34.

2. (Cancelled):

3. (Cancelled):

4. (Cancelled):

5. (Cancelled):

6. (Cancelled):

7. (Withdrawn: Currently Amended): The method of claim 1, wherein said the targeting moiety further comprises is a bacteriophage, wherein ~~on whose surface is a~~ said peptide, which binds specifically to an external domain of Hsp47, is on the surface of said bacteriophage.

8. (Withdrawn): The method of claim 1, wherein the agent further comprises a therapeutic moiety which is a toxin, a radioisotope or radionuclide, an antibody, or a nucleic acid which encodes a therapeutic gene.

9. (Withdrawn, Currently Amended): ~~The~~ A method of ~~claim 1,~~ for modulating the interaction of a tumor cell with an intracellular matrix, tumor cell invasion, migration or

motility of malignant cells, or tumor cell metastasis comprising contacting said tumor or malignant cell with a peptide of claim 34.

10. (Withdrawn, Currently Amended): A method for modulating a cell which expresses Hsp47 on its surface, comprising administering to the cell an effective amount of an agent comprising a targeting moiety which binds to an external domain of Hsp47, wherein said targeting moiety comprises a peptide of claim 34.

11. (Withdrawn): The method of claim 1, wherein the Hsp47 is human.

12. (Withdrawn, Currently Amended): A method for detecting a carcinoma in which Hsp47 is expressed on the surface of at least some cells, comprising contacting the carcinoma with a detectable agent comprising a targeting moiety which binds specifically to an external domain of Hsp47, wherein said targeting moiety comprises a peptide of claim 34.

13. (Cancelled):

14. (Withdrawn, Currently Amended): The method of claim 12, wherein the detectable agent comprises a detectable moiety which is detectable by MRI, X- Ray, gamma scintigraphy, or CT scanning.

15. (Withdrawn, Currently Amended): A method for detecting a cell which expresses Hsp47 on it surface, comprising administering to the cell a detectable agent comprising a targeting moiety which binds specifically to an external domain of Hsp47, wherein said targeting moiety comprises a peptide of claim 34.

16. (Withdrawn): The method of claim 12, wherein the Hsp47 is human.

17. (Cancelled):

18. (Cancelled):

19. (Cancelled):

20. (Cancelled):

21. (Cancelled):

22. (Cancelled):

23. (Cancelled):

24. (Cancelled):

25. (Cancelled):

26. (Cancelled):

27. (Cancelled):

28. (Cancelled):

29. (Currently Amended): An agent comprising a targeting moiety which binds specifically to an external domain of Hsp47 expressed on the surface of a cell, in an amount effective to modulate the activity of the cell, wherein said targeting moiety comprises the peptide of claim 24 34.

30. (Cancelled):

31. (Cancelled):

32. (Cancelled):

33. (Cancelled):

34. (Currently Amended): An isolated peptide which is:

- a) NWTLPQAQFAYL (SEQ. ID NO. 9) or
- b) KVPPALPSPWTS (SEQ. ID NO. 13).

35. (Currently Amended): A pharmaceutical composition comprising a peptide of claim ~~33~~ 34 and a pharmaceutically acceptable carrier.

36. (Currently Amended): The agent of claim 29, further comprising a therapeutic moiety which is a toxin, a radioisotope or radionuclide, an antibody, or a nucleic acid which encodes a therapeutic gene.

37. (Currently Amended): The agent of claim 29, wherein said agent further comprises comprising a detectable label agent, said detectable agent being which is detectable by MRI, X-Ray, gamma scintigraphy, or CT scanning.

38. (Cancelled):